LLLucie A. Low

Lucie A. Low

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lucie A. Low has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Microphysiological systems: What it takes for community adoption

    by Passley Hargrove-Grimes, Lucie A Low, Danilo A Tagle

    Microphysiological systems (MPS) are promising in vitro tools which could substantially improve the drug development process, particularly for underserved patient populations such as those with rare diseases, neural disorders, and diseases impacting pediatric populations. Currently, one of the major goals of the National Institutes of Health MPS program, led by the National Center for Advancing Translational Sciences (NCATS), is to demonstrate the utility of this emerging technology and help support the path to community adoption. However, community adoption of MPS technology has been hindered by a variety of factors including biological and technological challenges in device creation, issues with validation and standardization of MPS technology, and potential complications related to commercialization. In this brief Minireview, we offer an NCATS perspective on what current barriers exist to MPS adoption and provide an outlook on the future path to adoption of these in vitro tools.


  • Top Cited Papers

    Organs-on-chips: into the next decade

    by Lucie A. Low, Christine Mummery, Brian R. Berridge, Christopher P. Austin, Danilo A. Tagle

    Organs-on-chips (OoCs), also known as microphysiological systems or ‘tissue chips’ (the terms are synonymous), have attracted substantial interest in recent years owing to their potential to be informative at multiple stages of the drug discovery and development process. These innovative devices could provide insights into normal human organ function and disease pathophysiology, as well as more accurately predict the safety and efficacy of investigational drugs in humans. Therefore, they are likely to become useful additions to traditional preclinical cell culture methods and in vivo animal studies in the near term, and in some cases replacements for them in the longer term. In the past decade, the OoC field has seen dramatic advances in the sophistication of biology and engineering, in the demonstration of physiological relevance and in the range of applications. These advances have also revealed new challenges and opportunities, and expertise from multiple biomedical and engineering fields will be needed to fully realize the promise of OoCs for fundamental and translational applications. This Review provides a snapshot of this fast-evolving technology, discusses current applications and caveats for their implementation, and offers suggestions for directions in the next decade.


  • Tackling rare diseases: Clinical trials on chips

    by Sandra H Blumenrath, Bo Y Lee, Lucie Low, Ranjini Prithviraj, Danilo Tagle

    Designing and conducting clinical trials are extremely difficult in rare diseases. Adapting tissue chips for rare disease therapy development is pivotal in assuring that treatments are available, especially for severe diseases that are difficult to treat. Thus far, the NCATS-led National Institutes of Health (NIH) Tissue Chip program has focused on deploying the technology towards in vitro tools for safety and efficacy assessments of therapeutics. However, exploring the feasibility and best possible approach to expanding this focus towards the development phase of therapeutics is critical to moving the field of CToCs forward and increasing confidence with the use of tissue chips. The working group of stakeholders and experts convened by NCATS and the Drug Information Association (DIA) addresses important questions related to disease setting, test agents, study design, data collection, benefit/risk, and stakeholder engagement—exploring both current and future best use cases and important prerequisites for progress in this area.


  • Organs-on-a-Chip

    by Lucie A. Low, Margaret Sutherland, Nadya Lumelsky, Seila Selimovic, Martha S. Lundberg, Danilo A. Tagle

    Organs-on-chips, also known as “tissue chips” or microphysiological systems (MPS), are bioengineered microsystems capable of recreating aspects of human organ physiology and function and are in vitro tools with multiple applications in drug discovery and development. The ability to recapitulate human and animal tissues in physiologically relevant three-dimensional, multi-cellular environments allows applications in the drug development field, including; (1) use in assessing the safety and toxicity testing of potential therapeutics during early-stage preclinical drug development; (2) confirmation of drug/therapeutic efficacy in vitro; and (3) disease modeling of human tissues to recapitulate pathophysiology within specific subpopulations and even individuals, thereby advancing precision medicine efforts. This chapter will discuss the development and evolution of three-dimensional organ models over the past decade, and some of the opportunities offered by MPS technology that are not available through current standard two-dimensional cell cultures, or three-dimensional organoid systems. This chapter will outline future avenues of research in the MPS field, how cutting-edge biotechnology advances are expanding the applications for these systems, and discuss the current and future potential and challenges remaining for the field to address.


  • Tissue Chips in Space: Modeling Human Diseases in Microgravity

    by Lucie A. Low, Marc A. Giulianotti

    Purpose Microphysiological systems (MPS), also known as “organs-on-chips” or “tissue chips,” leverage recent advances in cell biology, tissue engineering, and microfabrication to create in vitro models of human organs and tissues. These systems offer promising solutions for modeling human physiology and disease in vitro and have multiple applications in areas where traditional cell culture and animal models fall short. Recently, the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) and the International Space Station (ISS) U.S. National Laboratory have coordinated efforts to facilitate the launch and use of these MPS platforms onboard the ISS. Here, we provide an introduction to the NIH Tissue Chips in Space initiative and an overview of the coordinated efforts between NIH and the ISS National Laboratory. We also highlight the current progress in addressing the scientific and technical challenges encountered in the development of these ambitious projects. Finally, we describe the potential impact of the Tissue Chips in Space program for the MPS field as well as the wider biomedical and health research communities.


  • ‘You-on-a-chip’ for precision medicine

    by Lucie A. Low, Danilo A. Tagle

    Introduction: This forward-thinking review will introduce microphysiological systems (MPS), also known as organs-on-chips or tissue chips and their potential utility in personalized medicine. The authors will explain how this technology could push precision medicine efforts forward, using scenarios of current and projected use of MPS in different disease and treatment scenarios. Areas covered: The research discussed will include highlights of the last half decade of MPS development, with background information on microphysiological systems including within the context of precision medicine. This review will cite examples on cancer, neurological disorders and rare disease scenarios where MPS could be integrated into the decision-making process for physicians and healthcare providers. Expert commentary: This review will discuss how microphysiological systems could be used in a variety of situations for medical diagnostics, understanding disease mechanisms, and development of therapeutic treatment plans. A useful place in precision medicine efforts exists for MPS to help eliminate some of the ‘guesswork’ in standard therapeutic recommendations, and to inform future treatment regimens for subgroups of individuals based on the systems biology and -omics-based readouts these platforms can produce.


  • Microphysiological Systems (Tissue Chips) and their Utility for Rare Disease Research

    by Lucie A. Low, Danilo A. Tagle

    The scientific and technological development of microphysiological systems (MPS) modeling organs-on-chips, or “tissue chips” (TCs), has progressed rapidly over the past decade. Stem cell research and microfluidic concepts have combined to lead to the development of microphysiological platforms representing an ever-expanding list of different human organ systems. In the context of rare diseases, these bioengineered microfluidics platforms hold promise for modeling of disorders and could prove useful in the screening and efficacy testing of existing therapeutics. Additionally, they have the potential for replacing and refining animal use for new drugs and clinical treatments, or could even act as surrogate human systems for testing of new therapeutics in the future, which could be particularly useful in populations of rare disease sufferers. This chapter will discuss the current state of tissue chip research, and challenges facing the field. Additionally, we will discuss how these devices are being used to model basic cellular and molecular phenotypes of rare diseases, holding promise to provide new tools for understanding of disease pathologies and screening and efficacy testing of potential therapeutics for drug discovery.


  • Tissue chips – innovative tools for drug development and disease modeling

    by L. A. Low, D. A. Tagle

    The high rate of failure during drug development is well-known, however recent advances in tissue engineering and microfabrication have contributed to the development of microphysiological systems (MPS), or ‘organs-on-chips’ that recapitulate the function of human organs. These ‘tissue chips’ could be utilized for drug screening and safety testing to potentially transform the early stages of the drug development process. They can also be used to model disease states, providing new tools for the understanding of disease mechanisms and pathologies, and assessing effectiveness of new therapies. In the future, they could be used to test new treatments and therapeutics in populations – via clinical trials-on-chips – and individuals, paving the way for precision medicine. Here we will discuss the wide-ranging and promising future of tissue chips, as well as challenges facing their development.


  • Comment on “Molecular and neural basis of contagious itch behavior in mice”

    by Jaquette Liljencrantz, Mark H. Pitcher, Lucie A. Low, Lucy Bauer, M. Catherine Bushnell

    Yu et al . (Reports, 10 March 2017, p. 1072 ) state that contagious itch occurs in mice based on imitative scratching in normal mice observing excessive scratching in genetically modified demonstrator mice. However, despite employing multiple behavioral analysis approaches, we were unable to extend these findings to normal mice observing the well-established histamine model of acute itch in demonstrator mice.